Tag: pay for delay

The number of reverse-payment patent settlements entered into by pharmaceutical companies in fiscal year 2015 declined from fiscal year 2014, marking a second annual decrease in such settlements...

The Federal Trade Commission has announced an agenda for its upcoming workshop on competition issues related to prescription drug markets. The workshop, titled “Understanding Competition in...

The Federal Trade Commission will hold a workshop on November 8, 2017 entitled, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics.” Acting FTC Chairman Maureen K...

In testimony presented to the U.S. House of Representatives’ Judiciary Committee Subcommittee on Regulatory Reform, Commerical and Antitrust Law, the Federal Trade Commission described its efforts to...

The Federal Trade Commission has approved the appointment of Quantic Regulatory Services, LLC as monitor in its case alleging that Endo Pharmaceuticals Inc. violated antitrust laws by using pay-for...

The Federal Trade Commission filed a complaint in federal district court alleging that Endo Pharmaceuticals Inc. and several other drug companies violated antitrust laws by using pay-for-delay...

Pharmaceutical companies entered into substantially fewer potential pay-for-delay patent dispute settlements in fiscal year 2014, according to a new FTC staff report. The report summarizes data on...

Related private monetary settlements may be credited against FTC fund

In Fiscal Year 2013, companies filed a total of 145 final patent dispute settlements, of which 29 created potential “pay-for-delay” agreements between branded and generic drug companies, according to...